Company intelligence / Profile preview

Merna Therapeutics

Austin, Texas, United Statesmersana.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company's lead product MRX34 was in Phase 1 clinical trials but was discontinued in September 2016 following multiple immune-related serious adverse events. The FDA placed a full clinical hold on the IND for MRX34, and the company subsequently discontinued development of MRX34 and its microRNA product pipeline.

Therapeutic areas: Oncology
Modalities: microRNA-based therapeuticsoligonucleotides
Industry: Biotech

Drug pipeline

1 asset

PR115002

Preclinical

Partnerships

Marina Biotech, Inc.Yale UniversityUniversity of ZurichRosetta Genomics Ltd.Polymun Scientific Immunbiologische Forschung GmbH

Beyond the preview

Go deeper on Merna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merna Therapeutics.

Explore the full profile